kinase panel

Reversible protein phosphorylation mediated by kinases and phosphatases plays an important role in cellular function regulations such as cell proliferation, apoptosis, subcellular translocation, inflammation and metabolism. The human kinase group includes 518 known protein kinases and about 20 lipid kinases. As we know that most of the kinase inhibitors target highly conserved ATP-binding sites, and highly selective drugs are pursued in terms of their superior safety profile compared to lower selectivity inhibitors, where lower selectivity drugs have off-target kinases inhibition,  inhibit cancer cell growth by relieving multiple kinase-dependent pathways, and induce toxic side effects in clinic.

作为专注于靶点驱动药物发现的一体化CRO，爱思益普（ICE Bioscience）在该领域已建立成熟的技术体系与评价平台。

  The kinase activity evaluation is critical for biochemical research, clinical diagnosis and drug targeted therapy for serious diseases. The study of a rapid, simple, sensitive and specific method for detecting kinase activity has a wide application prospect, and high-throughput screening (HTS) was used widely developing highly selective inhibitors, and so kinase profiling has become an important standard for the kinase inhibitors evaluation.

The ICE Bioscience has developed a kinase profiling platform based on HTRF and ADP-GLO methods to facilitate the development of new drugs, such as CDK kinase panel (16 types) and TK kinase panel (76 types), 60 mini kinase panel, 207 wild-type kinase panel and 310 kinase panel as shown in the appendix below.

Welcome any further discussion on the assay details and validation data.

Keywords： kinase profiling; Off-target effect; High throughput screening;

Pictures：

Figure 1 FDA-approved kinase inhibitors mapped onto the human kinome

References：

1. Attwood Misty M,Fabbro Doriano,Sokolov Aleksandr V et al. Trends in kinase drug discovery: targets, indications and inhibitor design.[J] .Nat Rev Drug Discov, 2021, 20: 839-861.

Validation data:

Appendix：

Mini kinase panel (60 kinases)
ABL1	CK1γ2	IGF1R	PDGFRα
AKT1	CK1γ3	IKK-alpha	PIM1
ALK 4	CK2a1	ITK	PKACα
AMPKα1/β1/γ1	CLK1	JAK3	PKCα
AurB	DAPK1	JNK1	PKD2
AXL	DCAMKL2	KDR	PLK1
BRAF	DYRK1B	LCK	PLK2
BRSK2	EGFR	MAP2K1	ROCK1
CDK1/CycE1	EPHB4	MAPKAPK2	RSK1
CDK18 < 如需了解相关技术服务详情，欢迎联系爱思益普（ICE Bioscience）获取定制化解决方案。 上一条：激酶谱筛选·激酶谱 全部 下一条：TRPV1受体 31 2022-08 最新动态 暗激酶组之外的磷酸酶与DUB靶点突围 2026-08-20 事件驱动药理学之PROTAC评价方法论 2026-08-20 好数据始于好方法之酶学检测开发要点 2026-08-20 从IL3依赖到激酶驱动的BaF3细胞模型 2026-08-20 八十五个获批药物背后的激酶选择性逻辑 2026-08-20 去泛素化酶与磷酸酶靶点的成药新机遇 2026-08-19 关于我们 公司简介 发展历程 团队管理 实验室VR 企业文化 平台服务 靶标检测 发现平台 中枢神经系统 安全药理学 细胞检测 更多 产品 蛋白产品 新闻中心 新闻资讯 《爱思学院》线上课 会议消息 技术长文 技术短文 招贤纳士 招聘人才 员工关怀 扫一扫关注 爱思益普公众号 友情链接： 国家政府网 国家卫健委 中华医学会 易科学 药渡网 Copyright © 2020- 2026爱思益普科技股份有限公司. All rights reserved. 京ICP备18000044号-1 网络：北京网站建设 问问思思 · 秒回实验问题×